Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:40:27.852Z.
Calculation as of: 2026-10-06T13:40:27.852Z.
Quote observation: 2026-10-06T13:39:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f2d634a7ba4b3af29dc0bd0f7aeccfce6021194a57d8f55324c803ee9ac920cb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Acurx Pharmaceuticals, Inc.
Market Cap
$5.59M
EV/EBITDA Ratio
N/A
Market Cap
$5.97M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | $5.59M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.47M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.40M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.40M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.38M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.83M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.25M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | N/A |
| Femasys Inc. (FEMY)vs › | $6.07M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
